Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

BC Partners and Bpifrance Acquire Biogaran from Servier

January 30, 2026

Pharmaceuticals

BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. The deal is supported by regulatory approvals (including EU clearances and French foreign investment screening), after a favourable opinion from Biogaran’s Social and Economic Committee.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

Charterhouse Acquires Labomar S.p.A.

September 7, 2023

Pharmaceuticals

Charterhouse Capital Partners has invested in Labomar S.p.A., partnering with founder and CEO Walter Bertin and existing minority shareholder Cleon Capital; Labomar's shares were delisted as part of the transaction. Charterhouse will support Labomar's next phase of growth via a buy-and-build strategy to consolidate fragmented markets and expand the company's CDMO capabilities across food supplements, medical devices and functional cosmetics.

CURE Pharmaceutical to Acquire Sera Labs for $20 Million

July 30, 2020

Consumer Products

CURE Pharmaceutical entered a memorandum of understanding to acquire 100% of privately held Sera Labs for $20 million in a deal composed primarily of CURE stock, with potential earn-outs of up to an additional $20 million. The acquisition adds Sera Labs' CBD-focused branded portfolio, DTC subscription model and retail/wholesale distribution (over 8,850 U.S. doors) to CURE's cGMP manufacturing and drug-delivery capabilities, with Sera Labs founder Nancy Duitch remaining in a leadership role.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.

Midatech Pharma to Acquire DARA BioSciences

June 4, 2015

Pharmaceuticals

Midatech Pharma PLC entered into a merger agreement to acquire DARA BioSciences, with DARA shareholders receiving Midatech ordinary shares via ADRs and a contingent value right (CVR). The deal gives Midatech a U.S. commercial footprint and an expanded oncology supportive-care portfolio; closing was expected in Q3/Q4 2015 subject to customary conditions and ADR listing.